Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

NCT07129252 is registered in ClinicalTrials.gov with Crinetics Pharmaceuticals Inc. as lead sponsor.

NCT NCT07129252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07129252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
Lead sponsor
Crinetics Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 26, 2025
Completion date
August 31, 2029
Enrollment
150 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine neoplasm, neuroendocrine tumors, sst2-positive neuroendocrine neoplasms